Analyzing the Role of Checkpoint Inhibitors for the Treatment of Melanoma
Ryan J. Sullivan, MD, discusses the role of checkpoint inhibitors in the treatment landscape for patients with melanoma.
Ryan J. Sullivan, MD, assistant professor of medicine, Harvard Medical School, assistant professor of hematology/oncology, Massachusetts General Hospital, discusses the role of checkpoint inhibitors in the treatment landscape for patients with melanoma.
Over the last decade, patients with both adjuvant and metastatic melanoma have had limited options until the last decade when immune checkpoint inhibitors were introduced to this space, says Sullivan. These advances include the approval of ipilimumab (Yervoy), nivolumab (Opdivo), and pembrolizumab (Keytruda), among others.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
